Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 5, 1996 - Issue 9
Submit an article Journal homepage
13
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Leading Article Biologicals & Immunologicals: Immunological adjuvants: Mechanisms of action and clinical applications

N Sheikh The Department of Immunology, St. Bartholomew's & the Royal London School of Medicine & Dentistry, London, EC1A 7BE, UK
,
P Rajananthanan The Department of Immunology, St. Bartholomew's & the Royal London School of Medicine & Dentistry, London, EC1A 7BE, UK
&
Wjw Morrow The Department of Immunology, St. Bartholomew's & the Royal London School of Medicine & Dentistry, London, EC1A 7BE, UK
Pages 1079-1099 | Published online: 03 Mar 2008

References to Primarv Literature

  • JENNER E: The origin of the vaccine inoculation. DN Shury, London (1801).
  • GLENNY AT, POPE CG, WADDINGTON H, WALLACE U: Immunological notes XVII to XXIV. J. Pathol. (1926) 29:31–40.
  • STEWART-TULL DES: Recommendations for the assessment of adjuvants (immunomodulators). In: Immunological Adjuvants and Vaccines. Gregoriadis G, Allison AC, Poste G (Eds.), Plenum Press, New York (1989):213-226. Breakdown of the requirements of adjuvant use, both clinical and experimental as well as laying down the ground rules to which new adjuvants being developed have to conform.
  • BOHLER-SOMMEREGGER K, LINDEMAYR H: Contact sensitivity to aluminium. Contact Dermatitis (1986) 15:278–281.
  • STANFIELD P, GALL D, BRACKEN PM: Single dose Inman-nisation against tetanus. Lancet (1973) 1:215–219.
  • VAN GINKEL MF, VAN DER VOET GB, VAN EIJK HG, DE •WOLFF FA: Aluminium binding to serum constituents: a role for transferrin and for citrate. J. Clin. Chem. Clin. Biocbem. (1990) 28:459–463.
  • FREUND J: The effect of paraffin oil and mycobacteria on antibody formation and sensitizatiom a review. Am. J. Clin. Pat hol. (1951) 21:646–656.
  • DAVENPORT FM, HENNESSY AV, ASKIN FB: Lack of adju-vant effect of AlP03 on purified typhoid and para-typhoid vaccines. Bull. %1110 (1965) 100:1139–1140.
  • KRUEGER JM, PAPPENHEIMER J12., KARNOVSKY ML: Sleep promoting effects of muramyl peptides. Proc. Natl. Acad. Sci. USA (1982) 159:68–76.
  • MACEK K: Overview on neuroinununomodulation and a possible role for serotonergic system. Adv. Immuno-pharmacol. (1989) 4:41–45.
  • OTANI T, UNE T, OSADA Y: Stimulation of non-specific resistance to infection by muroctasin. Arzneim-Forsch/Drug Res. (1988) 38:969–976.
  • ONO Y, IWASAKI T, SEKIGUCHI M, ONODERA T: Subacute toxicity of muroctasin in mice and dogs. Arzneim-Forsch/Drug Res. (1988) 38:1024–1027.
  • ICHIHARA N, KANAZAWA R, SASAKI 5: Phase I study and clinical pharmacological study of muroctasin. Arzneim-Forch/Drug Res. (1988) 38:1043–1069.
  • MARX PA, PEDERSEN NC, LERCHE NW: Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated Type D retrovirus vaccine. J Virol. (1986) 60:431–435,
  • MURPHY-CORB M, MARTIN LN, DAVISON-FAIRBURN B: A formalin inactivated whole SW vaccine confers protec-tion in macaques. Science (1989) 246:1293–1297.
  • RIBI E, MCLAUGHLIN CA, CANTRELL JL: Itrummotherapy for tumors with microbial constituents or their syn-thetic analogues: a review. In: Immunotherapy of Human Cancer. Higgins L (Ed.), Raven Press, New York (1978):131–154.
  • BEREK JS, CANTRELL JL, LICHTENSTEIN AK: Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine cancer modeL Cancer Res. (1984) 44:1871–1875.
  • RAYCHAUDHURI S, CARBONE F, TONKS M, MORROW WJW, HANNA N: Class I restricted cytotoxic T cell induc-tion with soluble antigen- Proc. Natl. Acad. Sci. USA (1992) 89:8308-8312. Experiments describing adjuvant mediated elicitation of CTL activity using soluble proteins gp120 and OVA.
  • SCHMOLKA IR: Polyalicylene oxide block co-polymers. In: Nonionic Surfactants. Shick IMJ (Ed.), Marcel Dekker (1966):30–37.
  • HUNTER RI, OLSEN MR, BENNETT B: Copolymer adju-vants and TiterMax. In: The Theory and Practical Applica-tion of Adjuvants. Stewart-Tull DES (Eds.), J Wiley & Sons, New York (1994):51–94.
  • FRIES LF, GORDON DM, RICIIARDS RL, EDAN JE, HOLLING-DALE MR: Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. &I. USA (1992) 89:358–392.
  • ZIGTERMAN GL SNIPPE H, JANSZE M, WILLERS JM: Adju-vants effects of nonionic block polymer surfactants on liposome-induced humoral immune response. J. Immu-nol. (1987) 138:220–225.
  • VERMA JN, WASSEF NM, WIRTZ R et al.: Phagocytosis of liposomes by macrophages - intracellular fate of liposo-mal malaria antigen. Biochim. Biophys. Acta (1991) 1066:229–238.
  • KENSIL CR, NEWMAN MJ, COUGHLIN RT, SOLTYSIK S, BEDORE D: The use of Stimulon adjuvant to boost vaccine response. Vaccine Research (1993) 2:273–281.
  • HYSLOP NS, MORROW AW: The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines. Res. Vet. Sci. (1969) 10(2):109–120.
  • GERMAIN RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T-lympho-cyte activatation. Cell (1994) 76:287-299. Comprehensive review encompassing class I and class II processing pathways.
  • ROELSE J, GROMME M, MOMBURG F, HAMMERLING G,NEEFJES J: Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recy-cling. J. Exp. Med. (1994) 180:1591–1597.
  • DEGEN E, COHENDOYLE MF, WILLIAMS DB: Efficient dissociation of the p88 chaperone from major histo-compatability complex class I molecules requires both 132-microglobuthi and peptide. J. Exp. Med. (1992) 175:1653–1661
  • MOSSIMAN TR, CHERWINSKI H, BOND MW, GIELDIN MA,COFFMAN RL: Two types of murine helper T-cell clones, definition according to profiles of lympholcine activi-ties and secretion proteins. J. Immunol. (1986) 136:2348–2357.
  • ROMAGNANI S: Human Thl and Th2 subsets: `Epptr si muove!'. European Cytokine Network (1992) 5(1):7–12.
  • ROMAGNANI S: T-helper cell subsets. Clin. Immuno-therapy (1995) 4(2):83–88.
  • VIVELLE S, NEEFJES J, LO I IEAU V et al.: Mice lacking theMHC class 11-associated invariant chain. Cell (1993) 72:635–648.
  • BIKOFF EK, HUANG L-Y, EPISKOPOU V et al.: Defectivemajor histocompatability complex class 11 assembly, transport, peptide acquisition, and CD4+ T-cell selection In mice lacking invariant chain expression. J. Exp. Med. (1993) 177:1699–1712.
  • RIBERDY JM, NEWCOMB JR, SURIVIAN MJ, BARBOSA JA, CRESWELL P: MA-DR molecules from an antigen proc-essing mutant cell line are associated with invariant chain peptides. Nature (1992) 360:474–477.
  • PETERS PJ, NEEFJES JJ, OORSCHOT V, PLOEGH HL, GEUZE HJ: Segregation of MHC class II molecules from the MHC class I molecules in the golgi complex for transport to lysosomal compartments. Nature (1991) 349:669–676.
  • SERCARZ EE, LEHMANN PV, AMETANI A et al.: Dominance and crypticity of T cell antigenic determinants. Ann. Rev. Immunol. (1993) 11:729–766.
  • HARDING C, SONG R: Phagocytic processing of exoge-nous particulate antigens by macrophages for presen-tation by class I ME1C molecules. J. Immunol. (1994) 153:4925-4933. Describes alternative class I processing pathways to the convention-ally accepted LMP, TAP dependent pathway.
  • RAYCHAUDHURI S, MORROW WJW: Can soluble antigens induce CDS. cytotoxic T-cell responses? A paradoxrevisited. Immunol. Today (1993) 14(7):344–348. Postulated mechanisms of eliciting cal responses against soluble proteins.
  • MOORE M, CARBONE F, BEVAN M: Introduction of sol-uble protein into the class I pathway of antigen proc-essing presenting. Cell (1988) 54:777-785. Attempts at forcing soluble protein from the class II to class I processing pathway.
  • HARIHAN K, BRASLAWSKY G, BLACK A, RAYCHAUDHURI S, HANNA N: The induction of cytotoxic T cells and tumour regression by soluble antigen formulation. Cancer Res. (1995) 55:3486–3489.
  • HORNUNG R, LONGO D, GOWDA V, KWAK L: Inductionof a CD8+ cytotoxic T-lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl (c(1-4)-N-acetylmu-ratnyl-L-alanyl-D-isoglutamine (GMDP). Ther. Immunol. (1995) 2: 7–14.
  • MANNHALTER JW, NEYCHEV HO, ZLABINGER GJ: Modu-lation of human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. (1985) 61:143–151.
  • HOLT LB: Developments in Diptheria Prophylaxis. Heine-mann, London (1950).
  • UEDE T, HUFF TF, ISHIZAKA K: Formation of IgE binding factors by rat T lymphocytes. V. Effect of adjuvant for the priming immunization on the nature of IgE binding factors formed by antigenic stimulation. J. Immunol. (1982) 129:1384–1390.
  • RAMANATHAN VD, BADENOCH-JONES P, TURK JI.: Com-plement activation by aluminium and zirconium com-pounds. Immunology (1979) 37:881–888.
  • HAMAOKE T, KATZ DH, BLOCH KJ, BENAXERRAF B: Hapten specific Ig E antibody responses in mice. I. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. J. Exp. Med. (1973) 138:306–311.
  • FREUND J: The mode of action of immunological adju-vants. Adv. Tuberculosis Res. (1956) 7:130–148.
  • SOUBERBIELLE BE, KNIGHT B, MORROW WJW et al.: Comparison of EL-2 and 11–4 transfected B16-F10 cells with a novel oil microemulsion adjuvant for B16-F10 whole cell tumour vaccine. Gene Therapy. In press.
  • DE SOUZA JB, PLAYFAIR JIIL: A novel adjuvant for usewith a blood stage malaria vaccine. Vaccine (1995)13(14):1316–1319. Comparative study of Quil A and AF in protection against murine malaria. The authors show cytokine profiles of protected mice as well as comparing the effectiveness of each adjuvant in protecting mice to subsequent challenge with P. yoelii.
  • NAIR S, ZHOU X, HUANG L, ROUSE B: Class I restricted cm recognition of a soluble protein delivered by liposomes containing lipophilic polysines. J. Immunol. Methods (1992) 152:237–243.
  • DALEK DL, HONG K, PAPIIADJOPOULOS D: Interactionof liposomes with macrophage cells. Biochim. Biophys. Acta Biorrtemb. (1990)1024(2):352–366.
  • GREGORIADIS G: Liposomes as immunological adju-vants: approaches to immunopotentiation including ligand mediated targeting to macrophages. Res. Immu-nol. (1992) 143:178–185 & 245–246.
  • COLLINS D, LITZINGER DC, HUANG L: Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three dif-ferent diacylsuccinylglycerols. Biochim. Biophys. Acta (1990) 1025:234–242.
  • OKU N, SHIBAMOTO S, ITO F, GONDO II, NANGO M: LowpH induced membrane fusion of lipid vesicles contain-ing proton-sensitive polymer. Biochemisby (1987) 26:8145–8150.
  • REDDY R, ZHOU F, HUANG L et al.: pli sensitive liposomes provide an efficient means of sensitising target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods (1991) 141:157-163. Study showing how antigen can be specifically delivered to either the class I or class II processing pathway.
  • DE HAAN A, TOMEE JFC, HUCHSHORN JP, WILSIIL'T J: Liposomes as an immunoadjuvant system for stimula-tion of mucos al and systemic antibody responses against inactivated measles virus administered in-tranasally to mice. Vaccine (1995) 13(14): 1320–1324.
  • DE-VRIES P, VAN BINNENDIJK RS, VAN DER MAREL P, VANWEZEL AL. Measles virus fusion protein presented in an immune stimulating complex (ISCOM) induces haemolysis-inhibiting and fusion inhibiting-antibod-ies, virus specific T-cells and protection in mice. J. Gen. Virol. (1988) 69(3):549–559.
  • AUDIBERT FM, LISE LD: Adjuvants: current status, clinical perspectives and future prospects. TIPS(1992)14:174-177. Brief review covering the major categories of adjuvants.
  • FLEBBE LM, BRALEY-MULLEN H: Immunopotentiating effects of the adjuvants SGP and Qull A. I. Antibody responses to T-dependent and T-independent antigens. Cell Immunol. (1986) 99(1):119–127.
  • TAKAHASHI H, TAKESHITA T, MOREIN B et al.: Inductionof CD8(+) cytotoxk T cells by immunization with puri-fied HIV-1 envelope protein in ISCOMs. Nature (1990) 344(6269):873–875.
  • ELLENS H, BENTZ J, MASON D, ZHANG F, WHITE JM:Fusion of influenza hemagglutinin expressing fi-broblasts with glycophorin bearing liposomes: role of hemagglutinin surface destiny. Biochemistry (1990) 29(41):9697–9707.
  • NEWMAN MJ, WU JY, GARDNER BH et al.: Saponin adju-vant induction of ovalbumin specific CD8(+) cytotoxic T-lymphocyte responses. J. Immunol. (1992) 148(8):2357–2362.
  • MOREIN B, VILLACRES-ERIKSSON M, AKERBLOM L et al.: Mechanisms behind the immune responses induced by immunostimulating complexes. AIDS Res. Hum. Ret. (1994) 10\(Suppl. 2):5109–5114.
  • HAMMOND SA, BOLLINGER RC, TOBERY TW, SILICIANO SF: Transporter-independent processing of HIV-1 enve-lope protein for recognition by CDS+ T-cells. Nature (1993) 364:158–161.
  • PFEIFER JD, WICK MJ, ROBERTS RI. et al.: Phagocyticprocessing of bacterial antigens for class I MHC pres-entation to T-cells. Nature (1993) 361:359–362.
  • SOUSA CE, GERMAIN RN: Major histocompatability complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged In phagocytosis. J. Exp. Med. (1995) 182:842-851.Recent paper describing cells that have the innate ability to process soluble protein through the class I pathway.
  • ORENTAS RM, HILDRETH JEK, OBAH E: Induction of CD4+ human cytolytic T-cells specific for 11W-infected cells by a gp160 subunit vaccine. (1990) 248:1237–1237.
  • AMADOR R, ROJAS M, POSADA MA, MORENO A, PAT-TAROYO ME: Strategies towards the design of a synthetic subunit malaria vaccine. Bailliere's Gun. Infect. Dis. (1995) 2(2):389–403.
  • D'ALESSANDRO U, LEACH A, DRAKELEY CJ et al.: Efficacytrial of malaria vaccine Spf66 in Gambian infants. Lancet (1995) 346(8973):462–467.
  • SCHWARTZ DH, GORSE G, CLEMENTS ML et al.: Induction of HIV-1 neutralising and syncytium-inhibiting anti-bodies in uninfected recipients of HIV-1111B gp120 subunit vaccine. Lancet (1993) 342(8863):69–73.
  • TRAUGER RJ, FERRE F, DIAGLE AE et al.: Effect of immu-nisation with inactivated gp120-depleted human immu-nodeficiency virus type 1 (HIV-1) immunogen on HIV-1 Immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. (1994) 169(6):1256–1264.
  • TURNER JL, TRAUGER RJ, DAIGLE AE, CARLO DJ: HIV-1 inummogen induction of IHV-1 specific delayed type hypersensitivity: results of a double-blind adjuvant-controlled, dose-ranging trial. AIDS (1994) 8(10):1429–1435.
  • OTE G, BARCHFELD GL, VAN NEST G: Enhancement ofhumoral response against human influenza vaccine with the simple submicron oil/water emulsion adju-vant MF59. Vaccine (1995) 13(16):1557–1562.
  • LANGENBERG AG, BURKE RI., ADAIR SF et al.: A recombi-nant glycoprotein vaccine for herpes simplex virus type 2: safety and incununogenicity. Ann. Intern. Med. (1995) 122(12):889–898.
  • HELLING F, ZHANG S, SHANG A et al.: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma pa-tients after administration with immunological adju-vant QS-21. Cancer Res. (1995) 55(13):2783–2788.
  • SCHULTZ N, ORATZ R, CHEN D et al.: Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine (1995) 13(9:503–508.
  • HUYGEN K, ABRAMOWICZ D, VANDENBUSSCHE P: Spleen cells cytokine secretion in.Mycobacteriumbovis BCG-infected mice. Infect. Immun. (1992)60:2880–2886.
  • ELSE KJ, FINKELMAN FD, MALISZEWSKI CR: Cytolcine mediated regulation of chronic intestinal helminth Infection.]. Exp. Med. (1994) 179:347–351.
  • TAYLOR ROBINSON AW, PHILLIPS RS, SEVERN A: The roleof Thl and Th2 cells in a rodent malaria infection. Science (1993) 260: 1931-1934.
  • SPINELLA S, MILON G, HONTEBEYERIE-JOSKOWICZ M: ACD4 Th2 cell line isolated from mice chronically in-fected with Trypanosoma cruzi induces an IgG2a poly-clonal response in vivo. Eur. J. Immunol (1991) 20:1045–1051.
  • MOSMANN T, SAD 5: The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol, Today (1996) 17(3):138–147. Comprehensive review outlining Thl and Th2 cytokines as well as which of the two predominates in various diseases, either in a protective or pathological role.
  • PLAYFAIR JHL, DE SOUZA JB: Recombinant ylFN is a potent adjuvant for a malaria vaccine in mice. J. Clin. Immunol. (1987) 67:5–10.
  • ALFONSO LC, SCHARTON TM, VIEIRA LQ: The adjuvanteffect of IL-12 in a vaccine against Leisbmania major. Science (1994) 263:235–237.
  • TANG YAV, GRAHAM B: Potential for directing appropriate responses to vaccines by cytokine manipulation. Clin. Immunother. (1996) 5:327-333. Very good review detailing the potential use of cytokines as adju-vants.
  • NASH AD, LOFTIIOUSE SA, BARCHAM GJ et al.: Recombi-nant cytokines as immunological adjuvants. Immunol. Cell Biol. (1993) 71\(Part 5):367–379.
  • O'HAGAN DT, JEFFREY H, DAVIS SS: Long-term antibodyresponses in mice following sub-cutaneous immuniza-tion with ovalbtunin entrapped in biodegradable mi-croparticles. Vaccine (1993) 11:965–999.
  • COOPER PD, MCCOMB C, STEELE EJ: The adjuvanticity ofalgammulin, a new vaccine adjuvant. Vaccine (1991) 9:408–415.
  • DEOL fIS, PALMER DG, DUNSMORE T, CARNEGIE PR: TheInfluence of gamma inulin and algamtnulin on the Immune response in sheep to a recombinant antigen of Taenia ovis. Vaccine (1995) 13:429–433.

References to Primarv Literature

  • KENSIL DR, MARCIANI DJ Saponin adjuvant. US 5057540 (1991).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.